{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-013051","form_type":"8-K","ticker":null,"cik":"0001173281","company_name":"NeuBase Therapeutics, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.298029+00:00","generated_at":"2026-06-12T07:17:27.456028+00:00","sec_items":["2.05","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"NeuBase halts program development, cuts 83% workforce, explores strategic alternatives","bullets":["Workforce reduced by ~83%; estimated $400K in severance and termination costs.","Board halts further development of all programs, including Stealth Editors gene editing candidates.","Company will explore strategic alternatives: acquisition, merger, business combination, or other transaction.","No timetable set for evaluation; no assurance that any transaction will be completed.","Decision not related to safety issues or negative regulatory feedback; cost-cutting focus."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-013051","json":"https://secwatch.observer/filing/0001558370-23-013051.json","markdown":"https://secwatch.observer/filing/0001558370-23-013051.md","text":"https://secwatch.observer/filing/0001558370-23-013051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173281/000155837023013051/0001558370-23-013051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173281/000155837023013051/nbse-20230728x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T07:17:27.456028+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8b3a4f037e9f6ac715440326022ebf08207044b0","claim":"NeuBase Therapeutics, Inc. announced a restructuring with charges of approximately $400,000 affecting different areas and functions (approximately 83%).","evidence_excerpt":"compensation grants and continuation of group health insurance coverage for a specified period to the affected employees. The Company estimates that it will incur approximately $400,000 of costs in connection with the reduction in workforce related to severance pay and other related termination benefits. The costs related to the Restructuring are subject to a","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173281/000155837023013051/0001558370-23-013051-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $400,000"},{"label":"Affected area","value":"different areas and functions"},{"label":"Headcount","value":"approximately 83%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}